Pharmacological therapies for diabetes, including rosiglitazone and pioglitazone, from the thiazolidinedione (TZD) class of PPAR-γ agonists, also increase circulating adiponectin [193]. The gene discussed is ADIPOQ; the disease is diabetes mellitus.